Our top pick for
Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our opinions or reviews. Learn how we make money.
Covetrus, Inc is a health information services business based in the US. Covetrus shares (CVET) are listed on the NASDAQ and all prices are listed in US Dollars. Covetrus employs 5,100 staff and has a trailing 12-month revenue of around USD$4.1 billion.
Since the stock market crash in March caused by coronavirus, Covetrus's share price has had significant positive movement.
Its last market close was USD$27.24, which is 55.95% up on its pre-crash value of USD$12 and 573.42% up on the lowest point reached during the March crash when the shares fell as low as USD$4.045.
If you had bought USD$1,000 worth of Covetrus shares at the start of February 2020, those shares would have been worth USD$485.34 at the bottom of the March crash, and if you held on to them, then as of the last market close they'd be worth USD$2,132.35.
|Latest market close||USD$27.24|
|52-week range||USD$4.045 - USD$26.96|
|50-day moving average||USD$22.9914|
|200-day moving average||USD$17.7856|
|Wall St. target price||USD$21.75|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||USD$0.3|
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
|1 week (2020-10-22)||-0.33%|
|1 month (2020-09-29)||10.78%|
|3 months (2020-07-29)||32.49%|
|6 months (2020-04-29)||135.03%|
|1 year (2019-10-29)||208.14%|
|2 years (2018-10-25)||N/A|
|3 years (2017-10-25)||N/A|
|5 years (2015-10-25)||N/A|
Valuing Covetrus stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Covetrus's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
Covetrus's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 41x. In other words, Covetrus shares trade at around 41x recent earnings.
That's relatively high compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The high P/E ratio could mean that investors are optimistic about the outlook for the shares or simply that they're over-valued.
Covetrus's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 1.2565. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.
The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into Covetrus's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.
Covetrus's EBITDA (earnings before interest, taxes, depreciation and amortisation) is USD$103 million.
The EBITDA is a measure of a Covetrus's overall financial performance and is widely used to measure a its profitability.
|Revenue TTM||USD$4.1 billion|
|Gross profit TTM||USD$749 million|
|Return on assets TTM||-1.02%|
|Return on equity TTM||-51.62%|
|Market capitalisation||USD$3.3 billion|
TTM: trailing 12 months
There are currently 7.7 million Covetrus shares held short by investors – that's known as Covetrus's "short interest". This figure is 14% down from 9.0 million last month.
There are a few different ways that this level of interest in shorting Covetrus shares can be evaluated.
Covetrus's "short interest ratio" (SIR) is the quantity of Covetrus shares currently shorted divided by the average quantity of Covetrus shares traded daily (recently around 809460.14644351). Covetrus's SIR currently stands at 9.56. In other words for every 100,000 Covetrus shares traded daily on the market, roughly 9560 shares are currently held short.
However Covetrus's short interest can also be evaluated against the total number of Covetrus shares, or, against the total number of tradable Covetrus shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Covetrus's short interest could be expressed as 0.06% of the outstanding shares (for every 100,000 Covetrus shares in existence, roughly 60 shares are currently held short) or 0.0864% of the tradable shares (for every 100,000 tradable Covetrus shares, roughly 86 shares are currently held short).
A SIR below 10% would generally be considered to indicate a fairly optimistic outlook for the share price, with fewer people currently willing to bet against Covetrus.
Find out more about how you can short Covetrus stock.
We're not expecting Covetrus to pay a dividend over the next 12 months.
Covetrus, Inc., together with its subsidiaries, operates as an animal-health technology and services company. It engages in the sale of animal-health consumable products, including proprietary and Covetrus branded products, small equipment, laboratory products, large equipment, equipment repair services, branded and generic pharmaceuticals, vaccines, surgical products, diagnostic tests, infection-control products, and vitamins and supplements to wholesale and retail customers. The company also offers value-added practice solutions that include financial services, equipment repair, inventory management, and e-commerce, as well as continuing education services for practitioners. In addition, it provides practice management software systems for veterinary practitioners and animal-health clinics, client communication services, reminders, data backup services, and hardware sales and support services. Further, the company engages in the distribution of finished goods pharmacy and specialty pharmaceutical compounding products, as well as e-commerce, shipping, manufacturer incentives, service fees, and data integration and support services. It serves animal-health and veterinary practices, and clinics in the companion-animal and equine markets primarily in North America, Europe, and the Asia Pacific. The company, formerly known as HS Spinco, Inc., was incorporated in 2018 and is headquartered in Portland, Maine.
Steps to owning and managing WK, with 24-hour and historical pricing before you buy.
Steps to owning and managing HCN, with 24-hour and historical pricing before you buy.
Steps to owning and managing VEL, with 24-hour and historical pricing before you buy.
Steps to owning and managing LEA, with 24-hour and historical pricing before you buy.
Steps to owning and managing LUB, with 24-hour and historical pricing before you buy.
Steps to owning and managing HCSG, with 24-hour and historical pricing before you buy.
Steps to owning and managing LAWS, with 24-hour and historical pricing before you buy.
Steps to owning and managing SWIR, with 24-hour and historical pricing before you buy.
Steps to owning and managing PFBC, with 24-hour and historical pricing before you buy.
Steps to owning and managing CSIQ, with 24-hour and historical pricing before you buy.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.